To test this premise, we treated CRC organoids from the radiotherapy-resistant cohort (CRC4 and CRC5) with the PI3K–Akt–mTOR pathway inhibitor dactolisib with and without radiotherapy. Here, MTOR is linked to colorectal carcinoma.